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Abstract
Recent evidence suggested that prostate cancer stem/progenitor cells (CSC) are responsible for cancer initiation as well as
disease progression. Unfortunately, conventional therapies are only effective in targeting the more differentiated cancer
cells and spare the CSCs. Here, we report that PSP, an active component extracted from the mushroom Turkey tail (also
known as Coriolus versicolor), is effective in targeting prostate CSCs. We found that treatment of the prostate cancer cell line
PC-3 with PSP led to the down-regulation of CSC markers (CD133 and CD44) in a time and dose-dependent manner.
Meanwhile, PSP treatment not only suppressed the ability of PC-3 cells to form prostaspheres under non-adherent culture
conditions, but also inhibited their tumorigenicity in vivo, further proving that PSP can suppress prostate CSC properties. To
investigate if the anti-CSC effect of PSP may lead to prostate cancer chemoprevention, transgenic mice (TgMAP) that
spontaneously develop prostate tumors were orally fed with PSP for 20 weeks. Whereas 100% of the mice that fed with
water only developed prostate tumors at the end of experiment, no tumors could be found in any of the mice fed with PSP,
suggesting that PSP treatment can completely inhibit prostate tumor formation. Our results not only demonstrated the
intriguing anti-CSC effect of PSP, but also revealed, for the first time, the surprising chemopreventive property of oral PSP
consumption against prostate cancer.
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Introduction
Prostate cancer (PCa) is the most common male malignancy in
western countries and represents a major disease burden in the
world. When diagnosed at an advanced stage where surgery is no
longer feasible, the only frontline treatment available is hormone
ablation therapy. Unfortunately, the majority of PCa patients
eventually relapse and develop hormone refractory PCa (HRPC),
a fatal and terminal stage regarded as incurable [1].
Chemoprevention is an ideal strategy for battling prostate
cancer, and a number of chemotherapeutic agents or natural food
supplements are currently being tested for their potential of
inhibiting prostate cancer development. For example, finasteride,
a 5-alpha reductase specific inhibitor, has been shown to reduce
prostate cancer incidence by 25% in a clinical trial [2]. Similarly,
dutasteride, an analog of finasteride, was also reported to
significantly inhibit prostate cancer development [3]. Despite of
the promising result, the side-effects associated with the finasteride
treatment remains the major concern for it to be used widely for
prostate chemoprevention. Therefore, bioactive food compounds
such as epigallocatechin-3-gallate or resveratrol [4,5,6] represents
an attractive alternative for prostate cancer chemoprevention,
mainly due to their relatively low toxicity. Unfortunately, most of
the previous studies have produced inconclusive results regarding
their chemopreventive potential.
Recent identification of prostate cancer stem cells (CSCs) [7] has
provided a new insight into prostate carcinogenesis. The ability of
these cancer stem cells to self-renew and differentiate into bulk
cancer cells suggested that they may be the origin of prostate cancer
[7]. Moreover, the highly resistant nature of these CSCs to different
chemotherapies suggested that CSCs may also contribute to
treatment failure and disease relapse [8]. Interestingly, a number
of bioactive food compounds have recently been shown to have
anti-CSC effect. For example, we recently reported that gamma-
tocotrienol extracted from palm oil inhibits prostasphere formation
ability and tumorigenicity of prostate cancer cells [9], suggesting
that gamma-tocotrienol is effective in suppressing prostate CSC
properties. In addition, a triterpene extracted from fruits was also
found to inhibit the self-renewal ability of liver CSCs and sensitize
the liver tumor to cisplatin treatment [10]. These findings highlight
the potential of bioactive food compounds as CSC targeting agent
either for the prevention or for the treatment of prostate cancer.
Here, we demonstrated that the polysaccharopeptide (PSP)
extracted from Turkey tail (known as Coriolus versicolor or Yun-zhi)
targets prostate CSCs in vitro and suppresses tumor formation in
vivo. Treatment of prostate cancer cell line PC-3 with PSP led to
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time and dose-dependent manner. Meanwhile, formation of
prostasphere, a major property of prostate CSCs, was completely
suppressed in PC-3 cells in the presence of PSP. Furthermore, PSP
pre-treatment significantly suppressed tumor initiation of PC-3
cells in immunocompromised mice, suggesting that PSP suppresses
the tumorigenicity of the PC-3 cells. More importantly, oral
feeding of transgenic mice (TgMAP) that spontaneously develop
prostate tumor with PSP was found to completely inhibit prostate
tumor formation. Our findings support that PSP may be a potent
chemopreventive agent against prostate cancer, possibly through
targeting of the prostate CSC population.
Results
Effects of PSP on CSC marker expression
PSP has previously shown to possess anti-cancer properties
[11,12,13], although the underlying mechanisms are still unclear.
To test if the anti-cancer effect of PSP is through targeting of CSC
properties, we first investigated if PSP treatment affects the
expression of prostate CSC markers in PC-3 cell line, which has
been reported to contain CSCs. PC-3 cells were treated with 250
and 500 mg/ml of PSP for either 48 or 72 hr, and the expression
of CSC markers such as CD133 or CD44 was examined by
western blotting. As shown in Figure 1B, protein expression of
CD133 was significantly down-regulated after PSP treatment in a
time and dose-dependent manner. Downregulation of CD44 was
also observed after PSP treatment, although the effect was less
obvious. However, examination of the mRNA level of both
CD133 and CD44 revealed that the downregulation of both
proteins by PSP is not due to inhibition of gene transcription (data
no shown). Nevertheless, these data suggest that PSP may be
effective in targeting the putative prostate CSCs.
To test if the down-regulation of CSC marker expression by
PSP is due to a decrease in cell viability, PC-3 cells treated with
PSP at different dosages (0, 5, 25, 125, 250 and 500 mg/ml) for 24,
48 or 72 hr were examined by MTT assay. Interestingly, 48 hr of
PSP treatment did not have any observable effects on cell viability,
even though the same treatments was found to significantly
suppress the expression of CSC markers (Figure 1B & 1C).
Meanwhile, PSP treatment also failed to induce cell cycle arrest or
apoptosis, as evidenced by the lack of sub-G1 population in the
result of flow cytometry analysis (Figure 1D). This was further
confirmed by examination of apoptosis-associated proteins (i.e.
Bax, Bcl-2 and cleaved PARP) (Figure 1E). However, the Akt/b-
catenin pathway, which is responsible for the enrichment of CSCs
in breast cancer, was drastically inhibited by PSP treatment. As
shown in Figure 1D, activation of AKT by phosphorylation at ser
473 was inhibited by PSP at both doses, which was accompanied
by complete disappearance of b-catenin expression (Figure 1E).
PSP inhibits prostasphere formation of prostate cancer
cells under non-adherent culture conditions
The ability to form prostaspheres in non-adherent culture is one
of the characteristics of prostate CSCs [14,15,16]. To confirm that
PSP treatment can inhibit prostate CSC properties, prostasphere
formation of PC-3 was studied in the presence or absence of PSP.
As shown in Figure 2A, culturing of both PC-3 and DU145 cells
for 14 days under non-adherent conditions results formation of
prostaspheres, further confirming the presence of a stem-like
population within both cell lines. Strikingly, addition of PSP into
the medium drastically inhibited prostasphere formation in both
cell lines. In particular, no prostaspheres was found in either cell
line in the presence of 500 mg/ml of PSP, suggesting that PSP
treatment significantly eliminated the prostate CSCs. To further
proved that PSP is effective in inhibiting prostasphere formation,
primary prostaspheres with enriched CSC population were
dissociated and re-seeded into non-adherent culture condition to
allow for the formation of secondary prostaspheres. Consistent
with the result from the primary spheroid formation assay, PSP
treatments significantly suppress the number of prostaspheres
found in each cell line, although the higher dosage of PSP
(500 mg/ml) was unable to completely eliminate all the secondary
prostaspheres. Nonetheless, these results suggest that PSP is
effective in suppressing the CSC properties of prostate cancer cells.
PSP significantly reduces the tumorigenicity of prostate
cancer cells in vivo
Since CSC is responsible for cancer initiation, it is possible that
PSP treatment may inhibit the tumor formation ability of PC-3 cells
in vivo. To test this hypothesis, we first treated PC-3 cells that stably
expressing the luciferase protein (PC-3-Luc) with PSP for 72 hr
before orthotopicallyinjected them into the SCID mice. As examined
b yb i o l u m i n e s c e n c ei m a g i n g ,a l lo ft h em i c et h a tw e r ei n j e c t e dw i t h
vehicle-pre-treated PC-3-luc cells formed tumors two weeks after the
implantation (Figure 3A). Intriguingly, three out of the eight mice that
were injected with PSP pre-treated PC-3-luc cells failed to develop
tumors even at week four post implantation (Figure 3A&B). The lack
of tumors in the PSP-pre-treated group was further confirmed by
examination of the mouse prostate glands at the end of the
experiment (Figure 3C). Taken together, our results suggested that
PSP was effective in reducing the tumorigenic potential of prostate
cancer cells, which is an essential characteristic of CSCs.
Oral administration of PSP fails to inhibit prostatic
intraepithelial neoplasia (PIN) development in TgMAP
mice
The effect of PSP on prostate CSCs supports the hypothesis that
it may have a chemopreventive effect against prostate cancer. To
test this hypothesis, we have employed a transgenic mouse model
that spontaneously develops adenocarcinoma of the prostate
(TgMAP) [17,18]. The TgMAP mice develop PIN between 16–
20weeks ofageand progress toprostate adenocarcinomaafterweek
24 (Figure 4A). Because PIN is considered as the pre-malignant
lesion and the most important risk factor of prostate cancer [19], we
first tested if PSP administration affected PIN development in
TgMAP mice. Five TgMAP mice (14-weeks old, at least 2 weeks
before PIN development) were fed with 200 mg/kg of PSP for 4
weeks. Four mice of the same age were fed with water only for the
same period of time. All mice were sacrificed at 20 weeks old and
prostatic tissues were collected and sectioned for histology. As
shown in Figure 4B&C, no differences were observed between the
control and PSP-treated TgMAP mice regarding to the gross
anatomy and the histology of the prostate gland. At low power
magnification, tissue sections from both groups retained glandular
structures, and at high power, PIN was detectable in both the
control and PSP-treated mice. These results suggest that 4 weeks of
PSP consumption was unable to stop the development of PIN.
Prolonging PSP consumption inhibits prostate cancer
development in TgMAP mice
The failure to inhibit PIN formation by PSP treatment may due
to insufficient dose or treatment length. We therefore tested if a
higher dose and longer period of PSP consumption may affect
prostate tumor formation using the same model. Five TgMAP
mice (8-weeks old) were fed with 300 mg/kg of PSP for a total of
20 weeks (Figure 5A). Four mice at the same age were again fed
PSP Targets Prostate Cancer Stem Cells
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sacrificed at 28 weeks old when prostate tumors were formed, with
prostatic tissues collected and sectioned for histology. As shown in
Figure 5B, tumors were found in different sections of the prostate
gland from all of the mice that were fed with water only.
Surprisingly, examination of all of the prostate section revealed
that none of the mice that were fed with PSP bare any prostate
tumors (Figure 5C), suggesting that PSP treatment completely
Figure 1. PSP down-regulates prostate CSC markers in PC-3 cells. A) Western blotting of prostate CSC markers CD44 and CD133 in PC-3 cells
after PSP treatment. Note that PSP significantly down-regulates both stem cell markers in a dose- and time-dependent manner. B) Viability of PC-3
cells after treatment with 5, 25, 125, 250 and 500 mg/ml of PSP for 48 or 72 hr was measured with MTT assay. Results are presented as mean 6 s.d. C)
Flow cytometry analysis of PC-3 cells after treatment with 250 mg/ml of PSP for 72 hr. Note that no significant difference in cell cycle distribution was
observed. D) Western blotting results for apoptotic markers (left panel) and stem cell maintenance proteins (right panel) in PC-3 cells after PSP
treatment. Note that no changes in Bax and Bcl-2 or cleavage of PARP were detected.
doi:10.1371/journal.pone.0019804.g001
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Meanwhile, whereas three of the PSP-fed mice were found to
have PIN, the other two mice were found to have completely
normal prostates (Figure 5D). Furthermore, consistent with the low
toxicity of PSP, long term consumption appears to have no side
effect on the mice, as judged by the body weight changes and
physical signs (data not shown) (Figure 5E). These findings strongly
suggest that oral intake of PSP may be a safe and effective
chemopreventive agent against prostate cancer.
Discussion
PSP has previously been demonstrated to induce apoptosis and
inhibit growth of a wide-range of cancer cells which includes
breast [20,21,22], liver [23] and prostate cancer [24], although the
mechanisms underlying its anti-cancer effects remain poorly
understood. Here, we demonstrated for the first time that PSP
has anti-CSC effects, as evidenced by the downregulation of CSC
markers and the suppression of prostasphere and tumor formation.
Prostate CSCs were first identified by Collins et al. in 2005
using CD44+/alpha2beta1hi/CD133+ as the cell surface markers
[25]. Using similar approaches, CSCs have also been identified in
prostate cancer cell lines such as LNCaP [26], DU145 [26,27] and
PC-3 [28,29]. These prostate CSCs not only express high level of
CD133 and CD44, but are also highly tumorigenic when
compared to the non-CSC population. The fact that PSP can
significantly suppress the expression of both CD133 and CD44, as
well as the tumorigenicity of PC-3 cells, clearly indicates the
Figure 2. Effects of PSP on CSC properties. A) Spheroid formation assay was performed with PC-3 and Du145 cells. Two hundred of cells were
seeded onto polyHEMA pre-coated plates and treated with either 500 mg/mL of PSP or vehicle for 14 days. The number of prostaspheres formed was
counted, and the result was presented as the mean 6 s.d. Note that c-T3 treatment efficiently suppresses the spheroid formation ability of PC-3 cells.
Image of the prostaspheres was captured under microscope. Note that no prostaspheres can be found in cells treated with 500 mg/mL of PSP. (B) PSP
inhibited the formation of secondary prostaspheres. Primary prostaspheres were dissociated and re-seeded into polyHEMA pre-coated plate. PSP was
added 24 hr after the plating. Note that prostasphere formation was inhibited by more than 70% and 90% in the presence of 250 mg/mL and 500 mg/
mL of PSP respectively. * P,0.001, ** P,0.0001, t test.
doi:10.1371/journal.pone.0019804.g002
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by Hsieh et al [24], PSP is effective on induction of apoptosis and
inhibition of cell proliferation in LNCaP cells. However, its effect
were much less prominent in androgen independent prostate
cancer cell lines such as PC-3. This is indeed consistent with our
finding, which showed that PSP can suppress CSC properties
without inducing any detectable cell cycle arrest or apoptosis.
Nevertheless, the finding that both Akt phosphorylation and b-
catenin expression were also down-regulated by PSP (Figure 1E)
suggests that PSP may act by inactivating the Pten/Akt/b-catenin
pathway to inhibit CSC renewal. This recently identified stem cell
maintenance pathway was shown to play a key role in the
regulation of prostate and mammary stem cell populations
[16,30]. Aberrant activation of the Akt/b-catenin pathway
through the knockdown of Pten was found to enrich the mammary
stem cell population, leading to the induction of hyperplastic
lesions in the mouse [30]. Similarly, knockdown of Pten in prostate
cancer cells was also found to enhance prostasphere formation
ability and tumorigenicity of the cells [16]. Therefore, the the loss
of ‘‘stemness’’ of prostate CSCs after PSP treatment may be due to
down-regulation of the Pten/AKT/b-catenin pathway.
One of the key properties of stem cells is their ability to form
spheres in non-adherent, serum-free conditions [31]. Indeed,
spheroid formation assays have recently been used to identify and
Figure 3. PSP inhibits tumorigenicity of PC-3 cells in vivo. A) Bioluminescent images of SCID mice orthotopically injected with PC-3-luc cells for
two weeks. SCID mice in the upper row were injected with vehicle-treated PC-3-luc cells, whereas mice in the bottom row were injected with PSP-
treated PC-3-luc cells. B) Table summarizes the percentages of mice developing detectable tumors at week 2. Approximately 40% of mice in the PSP
pretreated group did not form detectable tumors, whereas 100% tumor formation was found in the control group (p=0.07). C) Selected ex vivo
images of the prostate from both groups. Note that in PSP-treated mice with negative luciferase signal, no visible tumor were found in the prostate
tissue.
doi:10.1371/journal.pone.0019804.g003
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studies, both prostate cancer cell lines PC-3 and DU145 were able
to form prostaspheres in non-adherent culture [16], suggesting the
presence of CSCs within these cell lines. These primary prosta-
spheres, which are resistant to chemotherapeutic drugs [9], are
highly sensitive to PSP treatment (Figure 2A). In addition, the
secondary prostaspheres were significantly inhibited in a dose-
dependent manner (Figure 2B), supporting that PSP is effective in
eliminating prostate CSCs in vitro.
Prostate CSCs is believed to be origin of prostate tumor,
which have the ability to self-renew and differentiate into the
bulk tumor [35]. The fact that PSP pretreatment can
significantly inhibit the tumorigenicity of PC-3 cells (Figure 3)
not only highlights the anti-CSC effect of PSP, but also suggests
that PSP may have chemopreventive effects against prostate
cancer. We tested this hypothesis using a recently developed
transgenic mouse model of prostate cancer (TgMAP) [17,18].
T h es t e p w i s ed e v e l o p m e n to ft h ep r o s t a t et u m o r( f r o ml o w
Figure 4. Effect of PSP on PIN development in the TgMAP transgenic mouse model. A) Time frame of the PIN and PCa development in
TgMAP mice and the schedule of the PSP treatment. Fourteen-week old TgMAP mice were treated with 200 mg/kg of PSP by oral gavage feeding for
4 weeks and sacrificed at the time when PIN has developed (20 weeks old). The table summarizes the results of the histology examination of the
prostate from the vehicle- and PSP-treated TgMAP mice. C) Representative photos of the Hematoxylin & Eosin staining of the prostatic tissues from
the TgMAP mice. Note that both control- and PSP-treated TgMAP mice developed prostatic intraepithelial neoplasia (PIN), as indicated by the arrows.
doi:10.1371/journal.pone.0019804.g004
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the pathogenesis of human prostate cancer, although it may not
totally reflect the complex nature of prostate carcinogenesis.
Nonetheless, it allowed us to develop an optimal PSP treatment
dosage and time frame. Whereas four weeks of PSP oral
consumption at 200 mg/kg failed to produce any differences in
PIN development, complete inhibition of prostate tumor
formation was achieved after 20 weeks of oral PSP feeding at
300 mg/Kg. Meanwhile, the suppression of PIN formation by
PSP further suggested that the chemopreventive effect of PSP
may due to suppression of the tumor initiation at early stage.
The extremely low toxicity and the highly potent anti-CSC
effect of PSP warrants further evaluation of its chemopreventive
effect in human clinical trials.
In summary, we have demonstrated, for the first time, that PSP
treatment not only inhibits CSC properties, but also effectively
suppresses prostate tumor formation. Our results suggest that PSP
may be an effective agent for prostate cancer chemoprevention.
Figure 5. Effect of PSP on prostate tumor development of the TgMAP transgenic mouse model. A) Outline of the schedule for PSP
treatment. Eight-week old TgMAP mice were treated with 300 mg/kg of PSP by oral gavage feeding for 20 weeks and sacrificed at age of 28 weeks. B
& C) Representative photos of the Hematoxylin & Eosin staining of the prostate tissues from the vehicle and PSP-treated TgMAP mice. Note that
tumors were found in all of the mice that were treated with vehicle only but were absent in all the PSP-treated mice. D) The table summarizes the
results of the histology examination of the prostate tissues from the vehicle and PSP-treated TgMAP mice. *P,0.05 compared to control treatment by
Fisher’s exact test. E) Average body weight of the mice during the PSP treatment.
doi:10.1371/journal.pone.0019804.g005
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Polysaccharopeptide (PSP)
PSP extracted from Yun-zhi was kindly provided by Wonder
Herb Health Products, Ltd. The PSP powder was dissolved in
autoclaved Milli Q water at a concentration of 30 mg/ml by
mixing in a rotator at 4uC overnight. The PSP solution was stored
at 4uC. For cell culture study, PSP stock was sterilized with 0.2 mm
filtration prior to use. In the animal study, PSP was fed directly to
mice.
Cell lines and culture conditions
Prostate cancer cell lines PC-3 and DU145 (ATCC, Rockville,
MD) were maintained in RPMI 1640 medium (Invitrogen,
Carlsbad, CA) supplemented with 1% (w/v) penicillin-streptomy-
cin (Invitrogen, Carlsbad, CA) and 5% fetal bovine serum
(Invitrogen, Carlsbad, CA). All cell lines were kept at 37uCi na
5% CO2 environment. Luciferase-expressing PC-3 cell line was
generated in our previous study.
TgMAP prostate tumor model
TgMAP C57/BL6 mice at week 8 and 14 were administered
with PSP at 200 mg/kg for 4 weeks (n=5) or 300 mg/Kg for 20
weeks (n=5) respectively by oral gavage feeding (5 days per week).
Control group were fed with water only for the same period of
time. Mice were sacrificed (at the age of 20 weeks for 200 mg/Kg
treatment group and 28 weeks for the 300 mg/Kg treatment
group) and prostate tissues were collected, fixed in 10% formalin
and embedded in paraffin. The whole prostate was cut into 4 mm
sections and one in every five consecutive sections was stained with
H&E. Histology examination was performed by Dr. K.W. Chan
(pathologist, HKU). Statistical difference was determined by
Fisher’s exact test and was considered as significant if p,0.05.
Animal ethics was approved by the Committee on the Use of Live
Animals for Teaching and Research (CULATR) with the approval
no. of 1694-08. All animal handling procedures were carried out
according to the guidelines of the Committee on the Use of Live
Animals in Teaching and Research (CULATR), The University of
Hong Kong.
Spheroid formation assay
The spheroid formation assay was modified from a previously
reported protocol [36]. Briefly, PCa cells (200 cells per line) were
seeded onto 12-well polyHEMA (Sigma)-coated plates. Cells were
grown in DMEM/F12 medium (Invitrogen, Carlsbad, CA) for 14
days supplemented with 4 mg/mL insulin (Sigma), B27 (Invitro-
gen), 20 ng/mL EGF (Sigma), and 20 ng/mL basic FGF
(Invitrogen) with PSP at either 250 mg/mL and 500 mg/mL. For
serial passage of primary spheres, the primary spheres were treated
with PSP for the above doses for 72 h and subsequently collected,
dissociated with trypsin, and resuspended in DMEM/F12 medium
with the above supplements. Each experiment was repeated in
triplicate, and each data point represents the mean and standard
derivation. Statistical difference was determined by Student’s t-test
and was considered as significant if p,0.05.
Cell viability assay
Cell viability upon PSP treatment was measured by a 3-(4,5-
Dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
assay as described previously [37]. Briefly, cells were seeded on 96-
well plates and treated with different concentrations of PSP for the
indicated time. At the end of the treatment, MTT (Sigma, St.
Louis, MO) was added to each well, and wells were incubated for
4 hr at RT. DMSO was then added to each well to dissolve the
formazan crystals. The plate was incubated for a further 5 min at
RT, and the optical density (OD) was measured at a wavelength of
570 nm on a Labsystem multiscan microplate reader (Merck
Eurolab, Dietikon, Switzerland). All individual wells were analyzed
in triplicate. The percentage of cell viability was presented as the
OD ratio between the treated and untreated cells at the indicated
concentrations.
Western Blotting
Detailed experimental procedures have been described
previously [37]. Briefly, cells were lysed with RIPA buffer
(50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% deoxycholic
acid, 1% NP-40, 0.1% SDS) with protease inhibitors (1 mg/ml
aprotinin, 1 mg/ml leupeptin, 1 mM PMSF) and the protein
concentrations were determined using a DC Protein Assay Kit
(Bio-Rad, Hercules, CA). Proteins were resolved in SDS-
polyacrylamide gel by electrophoresis and then transferred onto
Hybond-P PVDF membrane (Amersham Biosciences, Piscat-
away, NJ). The membranes were blocked by 10% non-fat dry
milk in TBS-T or 3% non-fat dry milk in TBS and incubated
with primary antibodies at room temperature against Akt (ser
473), Bcl-2, PARP (Cell signaling, Technology Inc, Beverly,
MA), CD133 (Miltenyi Biotec, Auburn, CA), CD44, b-catenin
and b-actin (Santa Cruz Biotechnology, Santa Cruz, CA) for
1 hr at room temperature. After washing with TBS-T, the
membrane was incubated with either anti-mouse or anti-rabbit
IgG secondary antibodies, and the signals were visualized using
the ECL plus western blotting system (Amersham, Piscataway,
NJ).
Cell cycle analysis
Cells were fixed with 1 ml ice cold 70% ethanol at 4uC. After
fixation, cell pellets were collected by centrifugation, resuspended
with 500 ml PBS, and then incubated at 4uC a day before
performing flow cytometry. On the next day, cells were stained
with propidium iodide (50 mg/ml) and RNase (1 mg/ml) for
30 min. Cell cycle analysis was performed on a flow cytometer
EPICS profile analyzer and analyzed using the ModFit LT2.0
software (Coulter, Miami, FL).
Orthotopic implantation of PC-3-luc cells
The orthotopic model was established with procedures
described previously [38]. Briefly, eight-week-old CB-17 SCID
mice were anesthetized and placed under a dissecting microscope.
An incision at the midline of the abdomen was made, exposing the
dorsal prostate at the base of the bladder. Equal amounts of viable
PC3-luc cells (2.5610
4) with or without prior PSP treatment were
injected into the dorsal prostates of the mice. The organs were
replaced, and the abdomen was closed. Tumor development was
monitored by measuring the bioluminescent signal every two
weeks for six weeks after tumor implantation. Mice were sacrificed
at the end of the experiment and prostate tissues were collected for
physical examination. Statistical difference was determined by a
two-tailed t-test and was considered significant if p,0.05. All
surgical and animal handling procedures were carried out
according to the guidelines of the Committee on the Use of Live
Animals in Teaching and Research (CULATR), The University of
Hong Kong.
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